BRD2 and central nervous system cancer: A phosphoproteomic analysis was conducted in 132 samples (BrM, n = 50; BrM‐NAT, n = 18; Glioma, n = 53; Glioma‐NAT, n = 11) using our previously developed TiO2‐based phosphopeptide enrichment strategy.[19] For plasma data generation, a small number of samples were first used for label‐free quantitation (LFQ) and tandem mass tag (TMT)‐labeled proteomic analyses to obtain comprehensive and unbiased data.